Stratos Wealth Partners Reduces Stake in Eli Lilly

Institutional investor trims position in pharmaceutical giant

Apr. 8, 2026 at 9:10am

Got story updates? Submit your updates here. ›

Stratos Wealth Partners LTD., an institutional investor, decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.3% during the 4th quarter, according to the company's recent 13F filing with the Securities & Exchange Commission. Stratos Wealth Partners now owns 27,044 shares of the pharmaceutical company's stock, valued at $29,064,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a diverse portfolio of drugs and a strong research pipeline. Institutional investors closely monitor their holdings in Lilly and other major drugmakers, as these positions can significantly impact their overall investment performance.

The details

According to the 13F filing, Stratos Wealth Partners sold 5,266 shares of Eli Lilly during the fourth quarter, reducing its total position to 27,044 shares. The filing does not provide any additional context or rationale for the portfolio adjustment.

  • Stratos Wealth Partners filed the 13F report for the 4th quarter of 2026.

The players

Stratos Wealth Partners LTD.

An institutional investment firm that manages a portfolio of stocks, including a position in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Stratos Wealth Partners' Eli Lilly position is a relatively minor portfolio adjustment, but it highlights the ongoing scrutiny and shifting allocations among institutional investors in the pharmaceutical sector.